Global Orally Administered Vaccine Market Growth 2026-2032
The global Orally Administered Vaccine market size is predicted to grow from US$ 2908 million in 2025 to US$ 4307 million in 2032; it is expected to grow at a CAGR of 5.9% from 2026 to 2032.
Orally administered vaccines are of interest, as they elicit both systemic and mucosal immunities, in which mucosal immunity would neutralize the mucosa invading pathogen before the onset of an infection.
The oral vaccine market is driven by the growing demand for convenient and needle-free vaccination options, especially in pediatric and developing regions. Oral vaccines offer advantages like ease of administration, increased patient compliance, and simplified logistics, making them suitable for mass vaccination programs and reaching remote areas with limited healthcare infrastructure. The potential for improved vaccine stability and reduced production costs further contribute to market growth. However, the market also faces challenges, such as the need for enhanced vaccine stability to withstand gastrointestinal conditions and ensuring consistent efficacy across diverse populations. Additionally, regulatory complexities and the requirement for stringent safety and efficacy data can pose obstacles for oral vaccine manufacturers. To succeed in this market, companies must focus on innovative vaccine delivery technologies, conduct robust clinical trials, collaborate with global health agencies, and address public perception and trust in oral vaccine safety and effectiveness.
LP Information, Inc. (LPI) ' newest research report, the ?Orally Administered Vaccine Industry Forecast? looks at past sales and reviews total world Orally Administered Vaccine sales in 2025, providing a comprehensive analysis by region and market sector of projected Orally Administered Vaccine sales for 2026 through 2032. With Orally Administered Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Orally Administered Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Orally Administered Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Orally Administered Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Orally Administered Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Orally Administered Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Orally Administered Vaccine.
This report presents a comprehensive overview, market shares, and growth opportunities of Orally Administered Vaccine market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
Orally administered vaccines are of interest, as they elicit both systemic and mucosal immunities, in which mucosal immunity would neutralize the mucosa invading pathogen before the onset of an infection.
The oral vaccine market is driven by the growing demand for convenient and needle-free vaccination options, especially in pediatric and developing regions. Oral vaccines offer advantages like ease of administration, increased patient compliance, and simplified logistics, making them suitable for mass vaccination programs and reaching remote areas with limited healthcare infrastructure. The potential for improved vaccine stability and reduced production costs further contribute to market growth. However, the market also faces challenges, such as the need for enhanced vaccine stability to withstand gastrointestinal conditions and ensuring consistent efficacy across diverse populations. Additionally, regulatory complexities and the requirement for stringent safety and efficacy data can pose obstacles for oral vaccine manufacturers. To succeed in this market, companies must focus on innovative vaccine delivery technologies, conduct robust clinical trials, collaborate with global health agencies, and address public perception and trust in oral vaccine safety and effectiveness.
LP Information, Inc. (LPI) ' newest research report, the ?Orally Administered Vaccine Industry Forecast? looks at past sales and reviews total world Orally Administered Vaccine sales in 2025, providing a comprehensive analysis by region and market sector of projected Orally Administered Vaccine sales for 2026 through 2032. With Orally Administered Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Orally Administered Vaccine industry.
This Insight Report provides a comprehensive analysis of the global Orally Administered Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Orally Administered Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms? unique position in an accelerating global Orally Administered Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Orally Administered Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Orally Administered Vaccine.
This report presents a comprehensive overview, market shares, and growth opportunities of Orally Administered Vaccine market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Rotavirus Vaccine
- Cholera Vaccine
- Oral Polio Vaccine
- Other
- Public
- Private
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Merck
- GSK
- Sanofi
- Lanzhou Institute
- Serum Institute
- Valneva
- Shanghai United Cell
- Bibcol
- PaxVax
- Vabiotech
- Tiantan Biological
- EuBiologics
- Panacea Biotec Ltd
- Bio-Med
- Halfkin Bio-Pharmaceuticals
- What is the 10-year outlook for the global Orally Administered Vaccine market?
- What factors are driving Orally Administered Vaccine market growth, globally and by region?
- Which technologies are poised for the fastest growth by market and region?
- How do Orally Administered Vaccine market opportunities vary by end market size?
- How does Orally Administered Vaccine break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Orally Administered Vaccine Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Orally Administered Vaccine by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Orally Administered Vaccine by Country/Region, 2021, 2025 & 2032
2.2 Orally Administered Vaccine Segment by Type
2.2.1 Rotavirus Vaccine
2.2.2 Cholera Vaccine
2.2.3 Oral Polio Vaccine
2.2.4 Other
2.2.5 Orally Administered Vaccine Sales by Type
2.2.5.1 Global Orally Administered Vaccine Sales Market Share by Type (2021-2026)
2.2.5.2 Global Orally Administered Vaccine Revenue and Market Share by Type (2021-2026)
2.2.5.3 Global Orally Administered Vaccine Sale Price by Type (2021-2026)
2.3 Orally Administered Vaccine Segment by Application
2.3.1 Public
2.3.2 Private
2.3.3 Orally Administered Vaccine Sales by Application
2.3.3.1 Global Orally Administered Vaccine Sale Market Share by Application (2021-2026)
2.3.3.2 Global Orally Administered Vaccine Revenue and Market Share by Application (2021-2026)
2.3.3.3 Global Orally Administered Vaccine Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Orally Administered Vaccine Breakdown Data by Company
3.1.1 Global Orally Administered Vaccine Annual Sales by Company (2021-2026)
3.1.2 Global Orally Administered Vaccine Sales Market Share by Company (2021-2026)
3.2 Global Orally Administered Vaccine Annual Revenue by Company (2021-2026)
3.2.1 Global Orally Administered Vaccine Revenue by Company (2021-2026)
3.2.2 Global Orally Administered Vaccine Revenue Market Share by Company (2021-2026)
3.3 Global Orally Administered Vaccine Sale Price by Company
3.4 Key Manufacturers Orally Administered Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Orally Administered Vaccine Product Location Distribution
3.4.2 Players Orally Administered Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR ORALLY ADMINISTERED VACCINE BY GEOGRAPHIC REGION
4.1 World Historic Orally Administered Vaccine Market Size by Geographic Region (2021-2026)
4.1.1 Global Orally Administered Vaccine Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Orally Administered Vaccine Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Orally Administered Vaccine Market Size by Country/Region (2021-2026)
4.2.1 Global Orally Administered Vaccine Annual Sales by Country/Region (2021-2026)
4.2.2 Global Orally Administered Vaccine Annual Revenue by Country/Region (2021-2026)
4.3 Americas Orally Administered Vaccine Sales Growth
4.4 APAC Orally Administered Vaccine Sales Growth
4.5 Europe Orally Administered Vaccine Sales Growth
4.6 Middle East & Africa Orally Administered Vaccine Sales Growth
5 AMERICAS
5.1 Americas Orally Administered Vaccine Sales by Country
5.1.1 Americas Orally Administered Vaccine Sales by Country (2021-2026)
5.1.2 Americas Orally Administered Vaccine Revenue by Country (2021-2026)
5.2 Americas Orally Administered Vaccine Sales by Type (2021-2026)
5.3 Americas Orally Administered Vaccine Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Orally Administered Vaccine Sales by Region
6.1.1 APAC Orally Administered Vaccine Sales by Region (2021-2026)
6.1.2 APAC Orally Administered Vaccine Revenue by Region (2021-2026)
6.2 APAC Orally Administered Vaccine Sales by Type (2021-2026)
6.3 APAC Orally Administered Vaccine Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Orally Administered Vaccine by Country
7.1.1 Europe Orally Administered Vaccine Sales by Country (2021-2026)
7.1.2 Europe Orally Administered Vaccine Revenue by Country (2021-2026)
7.2 Europe Orally Administered Vaccine Sales by Type (2021-2026)
7.3 Europe Orally Administered Vaccine Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Orally Administered Vaccine by Country
8.1.1 Middle East & Africa Orally Administered Vaccine Sales by Country (2021-2026)
8.1.2 Middle East & Africa Orally Administered Vaccine Revenue by Country (2021-2026)
8.2 Middle East & Africa Orally Administered Vaccine Sales by Type (2021-2026)
8.3 Middle East & Africa Orally Administered Vaccine Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Orally Administered Vaccine
10.3 Manufacturing Process Analysis of Orally Administered Vaccine
10.4 Industry Chain Structure of Orally Administered Vaccine
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Orally Administered Vaccine Distributors
11.3 Orally Administered Vaccine Customer
12 WORLD FORECAST REVIEW FOR ORALLY ADMINISTERED VACCINE BY GEOGRAPHIC REGION
12.1 Global Orally Administered Vaccine Market Size Forecast by Region
12.1.1 Global Orally Administered Vaccine Forecast by Region (2027-2032)
12.1.2 Global Orally Administered Vaccine Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Orally Administered Vaccine Forecast by Type (2027-2032)
12.7 Global Orally Administered Vaccine Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Merck
13.1.1 Merck Company Information
13.1.2 Merck Orally Administered Vaccine Product Portfolios and Specifications
13.1.3 Merck Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Merck Main Business Overview
13.1.5 Merck Latest Developments
13.2 GSK
13.2.1 GSK Company Information
13.2.2 GSK Orally Administered Vaccine Product Portfolios and Specifications
13.2.3 GSK Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 GSK Main Business Overview
13.2.5 GSK Latest Developments
13.3 Sanofi
13.3.1 Sanofi Company Information
13.3.2 Sanofi Orally Administered Vaccine Product Portfolios and Specifications
13.3.3 Sanofi Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Sanofi Main Business Overview
13.3.5 Sanofi Latest Developments
13.4 Lanzhou Institute
13.4.1 Lanzhou Institute Company Information
13.4.2 Lanzhou Institute Orally Administered Vaccine Product Portfolios and Specifications
13.4.3 Lanzhou Institute Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Lanzhou Institute Main Business Overview
13.4.5 Lanzhou Institute Latest Developments
13.5 Serum Institute
13.5.1 Serum Institute Company Information
13.5.2 Serum Institute Orally Administered Vaccine Product Portfolios and Specifications
13.5.3 Serum Institute Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Serum Institute Main Business Overview
13.5.5 Serum Institute Latest Developments
13.6 Valneva
13.6.1 Valneva Company Information
13.6.2 Valneva Orally Administered Vaccine Product Portfolios and Specifications
13.6.3 Valneva Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Valneva Main Business Overview
13.6.5 Valneva Latest Developments
13.7 Shanghai United Cell
13.7.1 Shanghai United Cell Company Information
13.7.2 Shanghai United Cell Orally Administered Vaccine Product Portfolios and Specifications
13.7.3 Shanghai United Cell Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Shanghai United Cell Main Business Overview
13.7.5 Shanghai United Cell Latest Developments
13.8 Bibcol
13.8.1 Bibcol Company Information
13.8.2 Bibcol Orally Administered Vaccine Product Portfolios and Specifications
13.8.3 Bibcol Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Bibcol Main Business Overview
13.8.5 Bibcol Latest Developments
13.9 PaxVax
13.9.1 PaxVax Company Information
13.9.2 PaxVax Orally Administered Vaccine Product Portfolios and Specifications
13.9.3 PaxVax Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 PaxVax Main Business Overview
13.9.5 PaxVax Latest Developments
13.10 Vabiotech
13.10.1 Vabiotech Company Information
13.10.2 Vabiotech Orally Administered Vaccine Product Portfolios and Specifications
13.10.3 Vabiotech Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Vabiotech Main Business Overview
13.10.5 Vabiotech Latest Developments
13.11 Tiantan Biological
13.11.1 Tiantan Biological Company Information
13.11.2 Tiantan Biological Orally Administered Vaccine Product Portfolios and Specifications
13.11.3 Tiantan Biological Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Tiantan Biological Main Business Overview
13.11.5 Tiantan Biological Latest Developments
13.12 EuBiologics
13.12.1 EuBiologics Company Information
13.12.2 EuBiologics Orally Administered Vaccine Product Portfolios and Specifications
13.12.3 EuBiologics Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 EuBiologics Main Business Overview
13.12.5 EuBiologics Latest Developments
13.13 Panacea Biotec Ltd
13.13.1 Panacea Biotec Ltd Company Information
13.13.2 Panacea Biotec Ltd Orally Administered Vaccine Product Portfolios and Specifications
13.13.3 Panacea Biotec Ltd Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Panacea Biotec Ltd Main Business Overview
13.13.5 Panacea Biotec Ltd Latest Developments
13.14 Bio-Med
13.14.1 Bio-Med Company Information
13.14.2 Bio-Med Orally Administered Vaccine Product Portfolios and Specifications
13.14.3 Bio-Med Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 Bio-Med Main Business Overview
13.14.5 Bio-Med Latest Developments
13.15 Halfkin Bio-Pharmaceuticals
13.15.1 Halfkin Bio-Pharmaceuticals Company Information
13.15.2 Halfkin Bio-Pharmaceuticals Orally Administered Vaccine Product Portfolios and Specifications
13.15.3 Halfkin Bio-Pharmaceuticals Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.15.4 Halfkin Bio-Pharmaceuticals Main Business Overview
13.15.5 Halfkin Bio-Pharmaceuticals Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Orally Administered Vaccine Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for Orally Administered Vaccine by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for Orally Administered Vaccine by Country/Region, 2021, 2025 & 2032
2.2 Orally Administered Vaccine Segment by Type
2.2.1 Rotavirus Vaccine
2.2.2 Cholera Vaccine
2.2.3 Oral Polio Vaccine
2.2.4 Other
2.2.5 Orally Administered Vaccine Sales by Type
2.2.5.1 Global Orally Administered Vaccine Sales Market Share by Type (2021-2026)
2.2.5.2 Global Orally Administered Vaccine Revenue and Market Share by Type (2021-2026)
2.2.5.3 Global Orally Administered Vaccine Sale Price by Type (2021-2026)
2.3 Orally Administered Vaccine Segment by Application
2.3.1 Public
2.3.2 Private
2.3.3 Orally Administered Vaccine Sales by Application
2.3.3.1 Global Orally Administered Vaccine Sale Market Share by Application (2021-2026)
2.3.3.2 Global Orally Administered Vaccine Revenue and Market Share by Application (2021-2026)
2.3.3.3 Global Orally Administered Vaccine Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global Orally Administered Vaccine Breakdown Data by Company
3.1.1 Global Orally Administered Vaccine Annual Sales by Company (2021-2026)
3.1.2 Global Orally Administered Vaccine Sales Market Share by Company (2021-2026)
3.2 Global Orally Administered Vaccine Annual Revenue by Company (2021-2026)
3.2.1 Global Orally Administered Vaccine Revenue by Company (2021-2026)
3.2.2 Global Orally Administered Vaccine Revenue Market Share by Company (2021-2026)
3.3 Global Orally Administered Vaccine Sale Price by Company
3.4 Key Manufacturers Orally Administered Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Orally Administered Vaccine Product Location Distribution
3.4.2 Players Orally Administered Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR ORALLY ADMINISTERED VACCINE BY GEOGRAPHIC REGION
4.1 World Historic Orally Administered Vaccine Market Size by Geographic Region (2021-2026)
4.1.1 Global Orally Administered Vaccine Annual Sales by Geographic Region (2021-2026)
4.1.2 Global Orally Administered Vaccine Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic Orally Administered Vaccine Market Size by Country/Region (2021-2026)
4.2.1 Global Orally Administered Vaccine Annual Sales by Country/Region (2021-2026)
4.2.2 Global Orally Administered Vaccine Annual Revenue by Country/Region (2021-2026)
4.3 Americas Orally Administered Vaccine Sales Growth
4.4 APAC Orally Administered Vaccine Sales Growth
4.5 Europe Orally Administered Vaccine Sales Growth
4.6 Middle East & Africa Orally Administered Vaccine Sales Growth
5 AMERICAS
5.1 Americas Orally Administered Vaccine Sales by Country
5.1.1 Americas Orally Administered Vaccine Sales by Country (2021-2026)
5.1.2 Americas Orally Administered Vaccine Revenue by Country (2021-2026)
5.2 Americas Orally Administered Vaccine Sales by Type (2021-2026)
5.3 Americas Orally Administered Vaccine Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Orally Administered Vaccine Sales by Region
6.1.1 APAC Orally Administered Vaccine Sales by Region (2021-2026)
6.1.2 APAC Orally Administered Vaccine Revenue by Region (2021-2026)
6.2 APAC Orally Administered Vaccine Sales by Type (2021-2026)
6.3 APAC Orally Administered Vaccine Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe Orally Administered Vaccine by Country
7.1.1 Europe Orally Administered Vaccine Sales by Country (2021-2026)
7.1.2 Europe Orally Administered Vaccine Revenue by Country (2021-2026)
7.2 Europe Orally Administered Vaccine Sales by Type (2021-2026)
7.3 Europe Orally Administered Vaccine Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Orally Administered Vaccine by Country
8.1.1 Middle East & Africa Orally Administered Vaccine Sales by Country (2021-2026)
8.1.2 Middle East & Africa Orally Administered Vaccine Revenue by Country (2021-2026)
8.2 Middle East & Africa Orally Administered Vaccine Sales by Type (2021-2026)
8.3 Middle East & Africa Orally Administered Vaccine Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Orally Administered Vaccine
10.3 Manufacturing Process Analysis of Orally Administered Vaccine
10.4 Industry Chain Structure of Orally Administered Vaccine
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Orally Administered Vaccine Distributors
11.3 Orally Administered Vaccine Customer
12 WORLD FORECAST REVIEW FOR ORALLY ADMINISTERED VACCINE BY GEOGRAPHIC REGION
12.1 Global Orally Administered Vaccine Market Size Forecast by Region
12.1.1 Global Orally Administered Vaccine Forecast by Region (2027-2032)
12.1.2 Global Orally Administered Vaccine Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global Orally Administered Vaccine Forecast by Type (2027-2032)
12.7 Global Orally Administered Vaccine Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Merck
13.1.1 Merck Company Information
13.1.2 Merck Orally Administered Vaccine Product Portfolios and Specifications
13.1.3 Merck Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Merck Main Business Overview
13.1.5 Merck Latest Developments
13.2 GSK
13.2.1 GSK Company Information
13.2.2 GSK Orally Administered Vaccine Product Portfolios and Specifications
13.2.3 GSK Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 GSK Main Business Overview
13.2.5 GSK Latest Developments
13.3 Sanofi
13.3.1 Sanofi Company Information
13.3.2 Sanofi Orally Administered Vaccine Product Portfolios and Specifications
13.3.3 Sanofi Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Sanofi Main Business Overview
13.3.5 Sanofi Latest Developments
13.4 Lanzhou Institute
13.4.1 Lanzhou Institute Company Information
13.4.2 Lanzhou Institute Orally Administered Vaccine Product Portfolios and Specifications
13.4.3 Lanzhou Institute Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Lanzhou Institute Main Business Overview
13.4.5 Lanzhou Institute Latest Developments
13.5 Serum Institute
13.5.1 Serum Institute Company Information
13.5.2 Serum Institute Orally Administered Vaccine Product Portfolios and Specifications
13.5.3 Serum Institute Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Serum Institute Main Business Overview
13.5.5 Serum Institute Latest Developments
13.6 Valneva
13.6.1 Valneva Company Information
13.6.2 Valneva Orally Administered Vaccine Product Portfolios and Specifications
13.6.3 Valneva Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Valneva Main Business Overview
13.6.5 Valneva Latest Developments
13.7 Shanghai United Cell
13.7.1 Shanghai United Cell Company Information
13.7.2 Shanghai United Cell Orally Administered Vaccine Product Portfolios and Specifications
13.7.3 Shanghai United Cell Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Shanghai United Cell Main Business Overview
13.7.5 Shanghai United Cell Latest Developments
13.8 Bibcol
13.8.1 Bibcol Company Information
13.8.2 Bibcol Orally Administered Vaccine Product Portfolios and Specifications
13.8.3 Bibcol Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Bibcol Main Business Overview
13.8.5 Bibcol Latest Developments
13.9 PaxVax
13.9.1 PaxVax Company Information
13.9.2 PaxVax Orally Administered Vaccine Product Portfolios and Specifications
13.9.3 PaxVax Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 PaxVax Main Business Overview
13.9.5 PaxVax Latest Developments
13.10 Vabiotech
13.10.1 Vabiotech Company Information
13.10.2 Vabiotech Orally Administered Vaccine Product Portfolios and Specifications
13.10.3 Vabiotech Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 Vabiotech Main Business Overview
13.10.5 Vabiotech Latest Developments
13.11 Tiantan Biological
13.11.1 Tiantan Biological Company Information
13.11.2 Tiantan Biological Orally Administered Vaccine Product Portfolios and Specifications
13.11.3 Tiantan Biological Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.11.4 Tiantan Biological Main Business Overview
13.11.5 Tiantan Biological Latest Developments
13.12 EuBiologics
13.12.1 EuBiologics Company Information
13.12.2 EuBiologics Orally Administered Vaccine Product Portfolios and Specifications
13.12.3 EuBiologics Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.12.4 EuBiologics Main Business Overview
13.12.5 EuBiologics Latest Developments
13.13 Panacea Biotec Ltd
13.13.1 Panacea Biotec Ltd Company Information
13.13.2 Panacea Biotec Ltd Orally Administered Vaccine Product Portfolios and Specifications
13.13.3 Panacea Biotec Ltd Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.13.4 Panacea Biotec Ltd Main Business Overview
13.13.5 Panacea Biotec Ltd Latest Developments
13.14 Bio-Med
13.14.1 Bio-Med Company Information
13.14.2 Bio-Med Orally Administered Vaccine Product Portfolios and Specifications
13.14.3 Bio-Med Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.14.4 Bio-Med Main Business Overview
13.14.5 Bio-Med Latest Developments
13.15 Halfkin Bio-Pharmaceuticals
13.15.1 Halfkin Bio-Pharmaceuticals Company Information
13.15.2 Halfkin Bio-Pharmaceuticals Orally Administered Vaccine Product Portfolios and Specifications
13.15.3 Halfkin Bio-Pharmaceuticals Orally Administered Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.15.4 Halfkin Bio-Pharmaceuticals Main Business Overview
13.15.5 Halfkin Bio-Pharmaceuticals Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Orally Administered Vaccine Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Orally Administered Vaccine Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Rotavirus Vaccine
Table 4. Major Players of Cholera Vaccine
Table 5. Major Players of Oral Polio Vaccine
Table 6. Major Players of Other
Table 7. Global Orally Administered Vaccine Sales by Type (2021-2026) & (K Units)
Table 8. Global Orally Administered Vaccine Sales Market Share by Type (2021-2026)
Table 9. Global Orally Administered Vaccine Revenue by Type (2021-2026) & ($ million)
Table 10. Global Orally Administered Vaccine Revenue Market Share by Type (2021-2026)
Table 11. Global Orally Administered Vaccine Sale Price by Type (2021-2026) & (US$/Unit)
Table 12. Global Orally Administered Vaccine Sale by Application (2021-2026) & (K Units)
Table 13. Global Orally Administered Vaccine Sale Market Share by Application (2021-2026)
Table 14. Global Orally Administered Vaccine Revenue by Application (2021-2026) & ($ million)
Table 15. Global Orally Administered Vaccine Revenue Market Share by Application (2021-2026)
Table 16. Global Orally Administered Vaccine Sale Price by Application (2021-2026) & (US$/Unit)
Table 17. Global Orally Administered Vaccine Sales by Company (2021-2026) & (K Units)
Table 18. Global Orally Administered Vaccine Sales Market Share by Company (2021-2026)
Table 19. Global Orally Administered Vaccine Revenue by Company (2021-2026) & ($ millions)
Table 20. Global Orally Administered Vaccine Revenue Market Share by Company (2021-2026)
Table 21. Global Orally Administered Vaccine Sale Price by Company (2021-2026) & (US$/Unit)
Table 22. Key Manufacturers Orally Administered Vaccine Producing Area Distribution and Sales Area
Table 23. Players Orally Administered Vaccine Products Offered
Table 24. Orally Administered Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 25. New Products and Potential Entrants
Table 26. Market M&A Activity & Strategy
Table 27. Global Orally Administered Vaccine Sales by Geographic Region (2021-2026) & (K Units)
Table 28. Global Orally Administered Vaccine Sales Market Share Geographic Region (2021-2026)
Table 29. Global Orally Administered Vaccine Revenue by Geographic Region (2021-2026) & ($ millions)
Table 30. Global Orally Administered Vaccine Revenue Market Share by Geographic Region (2021-2026)
Table 31. Global Orally Administered Vaccine Sales by Country/Region (2021-2026) & (K Units)
Table 32. Global Orally Administered Vaccine Sales Market Share by Country/Region (2021-2026)
Table 33. Global Orally Administered Vaccine Revenue by Country/Region (2021-2026) & ($ millions)
Table 34. Global Orally Administered Vaccine Revenue Market Share by Country/Region (2021-2026)
Table 35. Americas Orally Administered Vaccine Sales by Country (2021-2026) & (K Units)
Table 36. Americas Orally Administered Vaccine Sales Market Share by Country (2021-2026)
Table 37. Americas Orally Administered Vaccine Revenue by Country (2021-2026) & ($ millions)
Table 38. Americas Orally Administered Vaccine Sales by Type (2021-2026) & (K Units)
Table 39. Americas Orally Administered Vaccine Sales by Application (2021-2026) & (K Units)
Table 40. APAC Orally Administered Vaccine Sales by Region (2021-2026) & (K Units)
Table 41. APAC Orally Administered Vaccine Sales Market Share by Region (2021-2026)
Table 42. APAC Orally Administered Vaccine Revenue by Region (2021-2026) & ($ millions)
Table 43. APAC Orally Administered Vaccine Sales by Type (2021-2026) & (K Units)
Table 44. APAC Orally Administered Vaccine Sales by Application (2021-2026) & (K Units)
Table 45. Europe Orally Administered Vaccine Sales by Country (2021-2026) & (K Units)
Table 46. Europe Orally Administered Vaccine Revenue by Country (2021-2026) & ($ millions)
Table 47. Europe Orally Administered Vaccine Sales by Type (2021-2026) & (K Units)
Table 48. Europe Orally Administered Vaccine Sales by Application (2021-2026) & (K Units)
Table 49. Middle East & Africa Orally Administered Vaccine Sales by Country (2021-2026) & (K Units)
Table 50. Middle East & Africa Orally Administered Vaccine Revenue Market Share by Country (2021-2026)
Table 51. Middle East & Africa Orally Administered Vaccine Sales by Type (2021-2026) & (K Units)
Table 52. Middle East & Africa Orally Administered Vaccine Sales by Application (2021-2026) & (K Units)
Table 53. Key Market Drivers & Growth Opportunities of Orally Administered Vaccine
Table 54. Key Market Challenges & Risks of Orally Administered Vaccine
Table 55. Key Industry Trends of Orally Administered Vaccine
Table 56. Orally Administered Vaccine Raw Material
Table 57. Key Suppliers of Raw Materials
Table 58. Orally Administered Vaccine Distributors List
Table 59. Orally Administered Vaccine Customer List
Table 60. Global Orally Administered Vaccine Sales Forecast by Region (2027-2032) & (K Units)
Table 61. Global Orally Administered Vaccine Revenue Forecast by Region (2027-2032) & ($ millions)
Table 62. Americas Orally Administered Vaccine Sales Forecast by Country (2027-2032) & (K Units)
Table 63. Americas Orally Administered Vaccine Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 64. APAC Orally Administered Vaccine Sales Forecast by Region (2027-2032) & (K Units)
Table 65. APAC Orally Administered Vaccine Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 66. Europe Orally Administered Vaccine Sales Forecast by Country (2027-2032) & (K Units)
Table 67. Europe Orally Administered Vaccine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Middle East & Africa Orally Administered Vaccine Sales Forecast by Country (2027-2032) & (K Units)
Table 69. Middle East & Africa Orally Administered Vaccine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 70. Global Orally Administered Vaccine Sales Forecast by Type (2027-2032) & (K Units)
Table 71. Global Orally Administered Vaccine Revenue Forecast by Type (2027-2032) & ($ millions)
Table 72. Global Orally Administered Vaccine Sales Forecast by Application (2027-2032) & (K Units)
Table 73. Global Orally Administered Vaccine Revenue Forecast by Application (2027-2032) & ($ millions)
Table 74. Merck Basic Information, Orally Administered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 75. Merck Orally Administered Vaccine Product Portfolios and Specifications
Table 76. Merck Orally Administered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 77. Merck Main Business
Table 78. Merck Latest Developments
Table 79. GSK Basic Information, Orally Administered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 80. GSK Orally Administered Vaccine Product Portfolios and Specifications
Table 81. GSK Orally Administered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 82. GSK Main Business
Table 83. GSK Latest Developments
Table 84. Sanofi Basic Information, Orally Administered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 85. Sanofi Orally Administered Vaccine Product Portfolios and Specifications
Table 86. Sanofi Orally Administered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 87. Sanofi Main Business
Table 88. Sanofi Latest Developments
Table 89. Lanzhou Institute Basic Information, Orally Administered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 90. Lanzhou Institute Orally Administered Vaccine Product Portfolios and Specifications
Table 91. Lanzhou Institute Orally Administered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 92. Lanzhou Institute Main Business
Table 93. Lanzhou Institute Latest Developments
Table 94. Serum Institute Basic Information, Orally Administered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 95. Serum Institute Orally Administered Vaccine Product Portfolios and Specifications
Table 96. Serum Institute Orally Administered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 97. Serum Institute Main Business
Table 98. Serum Institute Latest Developments
Table 99. Valneva Basic Information, Orally Administered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 100. Valneva Orally Administered Vaccine Product Portfolios and Specifications
Table 101. Valneva Orally Administered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 102. Valneva Main Business
Table 103. Valneva Latest Developments
Table 104. Shanghai United Cell Basic Information, Orally Administered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 105. Shanghai United Cell Orally Administered Vaccine Product Portfolios and Specifications
Table 106. Shanghai United Cell Orally Administered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 107. Shanghai United Cell Main Business
Table 108. Shanghai United Cell Latest Developments
Table 109. Bibcol Basic Information, Orally Administered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 110. Bibcol Orally Administered Vaccine Product Portfolios and Specifications
Table 111. Bibcol Orally Administered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 112. Bibcol Main Business
Table 113. Bibcol Latest Developments
Table 114. PaxVax Basic Information, Orally Administered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 115. PaxVax Orally Administered Vaccine Product Portfolios and Specifications
Table 116. PaxVax Orally Administered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 117. PaxVax Main Business
Table 118. PaxVax Latest Developments
Table 119. Vabiotech Basic Information, Orally Administered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 120. Vabiotech Orally Administered Vaccine Product Portfolios and Specifications
Table 121. Vabiotech Orally Administered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 122. Vabiotech Main Business
Table 123. Vabiotech Latest Developments
Table 124. Tiantan Biological Basic Information, Orally Administered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 125. Tiantan Biological Orally Administered Vaccine Product Portfolios and Specifications
Table 126. Tiantan Biological Orally Administered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 127. Tiantan Biological Main Business
Table 128. Tiantan Biological Latest Developments
Table 129. EuBiologics Basic Information, Orally Administered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 130. EuBiologics Orally Administered Vaccine Product Portfolios and Specifications
Table 131. EuBiologics Orally Administered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 132. EuBiologics Main Business
Table 133. EuBiologics Latest Developments
Table 134. Panacea Biotec Ltd Basic Information, Orally Administered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 135. Panacea Biotec Ltd Orally Administered Vaccine Product Portfolios and Specifications
Table 136. Panacea Biotec Ltd Orally Administered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 137. Panacea Biotec Ltd Main Business
Table 138. Panacea Biotec Ltd Latest Developments
Table 139. Bio-Med Basic Information, Orally Administered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 140. Bio-Med Orally Administered Vaccine Product Portfolios and Specifications
Table 141. Bio-Med Orally Administered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 142. Bio-Med Main Business
Table 143. Bio-Med Latest Developments
Table 144. Halfkin Bio-Pharmaceuticals Basic Information, Orally Administered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 145. Halfkin Bio-Pharmaceuticals Orally Administered Vaccine Product Portfolios and Specifications
Table 146. Halfkin Bio-Pharmaceuticals Orally Administered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 147. Halfkin Bio-Pharmaceuticals Main Business
Table 148. Halfkin Bio-Pharmaceuticals Latest Developments
Table 1. Orally Administered Vaccine Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. Orally Administered Vaccine Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Rotavirus Vaccine
Table 4. Major Players of Cholera Vaccine
Table 5. Major Players of Oral Polio Vaccine
Table 6. Major Players of Other
Table 7. Global Orally Administered Vaccine Sales by Type (2021-2026) & (K Units)
Table 8. Global Orally Administered Vaccine Sales Market Share by Type (2021-2026)
Table 9. Global Orally Administered Vaccine Revenue by Type (2021-2026) & ($ million)
Table 10. Global Orally Administered Vaccine Revenue Market Share by Type (2021-2026)
Table 11. Global Orally Administered Vaccine Sale Price by Type (2021-2026) & (US$/Unit)
Table 12. Global Orally Administered Vaccine Sale by Application (2021-2026) & (K Units)
Table 13. Global Orally Administered Vaccine Sale Market Share by Application (2021-2026)
Table 14. Global Orally Administered Vaccine Revenue by Application (2021-2026) & ($ million)
Table 15. Global Orally Administered Vaccine Revenue Market Share by Application (2021-2026)
Table 16. Global Orally Administered Vaccine Sale Price by Application (2021-2026) & (US$/Unit)
Table 17. Global Orally Administered Vaccine Sales by Company (2021-2026) & (K Units)
Table 18. Global Orally Administered Vaccine Sales Market Share by Company (2021-2026)
Table 19. Global Orally Administered Vaccine Revenue by Company (2021-2026) & ($ millions)
Table 20. Global Orally Administered Vaccine Revenue Market Share by Company (2021-2026)
Table 21. Global Orally Administered Vaccine Sale Price by Company (2021-2026) & (US$/Unit)
Table 22. Key Manufacturers Orally Administered Vaccine Producing Area Distribution and Sales Area
Table 23. Players Orally Administered Vaccine Products Offered
Table 24. Orally Administered Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 25. New Products and Potential Entrants
Table 26. Market M&A Activity & Strategy
Table 27. Global Orally Administered Vaccine Sales by Geographic Region (2021-2026) & (K Units)
Table 28. Global Orally Administered Vaccine Sales Market Share Geographic Region (2021-2026)
Table 29. Global Orally Administered Vaccine Revenue by Geographic Region (2021-2026) & ($ millions)
Table 30. Global Orally Administered Vaccine Revenue Market Share by Geographic Region (2021-2026)
Table 31. Global Orally Administered Vaccine Sales by Country/Region (2021-2026) & (K Units)
Table 32. Global Orally Administered Vaccine Sales Market Share by Country/Region (2021-2026)
Table 33. Global Orally Administered Vaccine Revenue by Country/Region (2021-2026) & ($ millions)
Table 34. Global Orally Administered Vaccine Revenue Market Share by Country/Region (2021-2026)
Table 35. Americas Orally Administered Vaccine Sales by Country (2021-2026) & (K Units)
Table 36. Americas Orally Administered Vaccine Sales Market Share by Country (2021-2026)
Table 37. Americas Orally Administered Vaccine Revenue by Country (2021-2026) & ($ millions)
Table 38. Americas Orally Administered Vaccine Sales by Type (2021-2026) & (K Units)
Table 39. Americas Orally Administered Vaccine Sales by Application (2021-2026) & (K Units)
Table 40. APAC Orally Administered Vaccine Sales by Region (2021-2026) & (K Units)
Table 41. APAC Orally Administered Vaccine Sales Market Share by Region (2021-2026)
Table 42. APAC Orally Administered Vaccine Revenue by Region (2021-2026) & ($ millions)
Table 43. APAC Orally Administered Vaccine Sales by Type (2021-2026) & (K Units)
Table 44. APAC Orally Administered Vaccine Sales by Application (2021-2026) & (K Units)
Table 45. Europe Orally Administered Vaccine Sales by Country (2021-2026) & (K Units)
Table 46. Europe Orally Administered Vaccine Revenue by Country (2021-2026) & ($ millions)
Table 47. Europe Orally Administered Vaccine Sales by Type (2021-2026) & (K Units)
Table 48. Europe Orally Administered Vaccine Sales by Application (2021-2026) & (K Units)
Table 49. Middle East & Africa Orally Administered Vaccine Sales by Country (2021-2026) & (K Units)
Table 50. Middle East & Africa Orally Administered Vaccine Revenue Market Share by Country (2021-2026)
Table 51. Middle East & Africa Orally Administered Vaccine Sales by Type (2021-2026) & (K Units)
Table 52. Middle East & Africa Orally Administered Vaccine Sales by Application (2021-2026) & (K Units)
Table 53. Key Market Drivers & Growth Opportunities of Orally Administered Vaccine
Table 54. Key Market Challenges & Risks of Orally Administered Vaccine
Table 55. Key Industry Trends of Orally Administered Vaccine
Table 56. Orally Administered Vaccine Raw Material
Table 57. Key Suppliers of Raw Materials
Table 58. Orally Administered Vaccine Distributors List
Table 59. Orally Administered Vaccine Customer List
Table 60. Global Orally Administered Vaccine Sales Forecast by Region (2027-2032) & (K Units)
Table 61. Global Orally Administered Vaccine Revenue Forecast by Region (2027-2032) & ($ millions)
Table 62. Americas Orally Administered Vaccine Sales Forecast by Country (2027-2032) & (K Units)
Table 63. Americas Orally Administered Vaccine Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 64. APAC Orally Administered Vaccine Sales Forecast by Region (2027-2032) & (K Units)
Table 65. APAC Orally Administered Vaccine Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 66. Europe Orally Administered Vaccine Sales Forecast by Country (2027-2032) & (K Units)
Table 67. Europe Orally Administered Vaccine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Middle East & Africa Orally Administered Vaccine Sales Forecast by Country (2027-2032) & (K Units)
Table 69. Middle East & Africa Orally Administered Vaccine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 70. Global Orally Administered Vaccine Sales Forecast by Type (2027-2032) & (K Units)
Table 71. Global Orally Administered Vaccine Revenue Forecast by Type (2027-2032) & ($ millions)
Table 72. Global Orally Administered Vaccine Sales Forecast by Application (2027-2032) & (K Units)
Table 73. Global Orally Administered Vaccine Revenue Forecast by Application (2027-2032) & ($ millions)
Table 74. Merck Basic Information, Orally Administered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 75. Merck Orally Administered Vaccine Product Portfolios and Specifications
Table 76. Merck Orally Administered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 77. Merck Main Business
Table 78. Merck Latest Developments
Table 79. GSK Basic Information, Orally Administered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 80. GSK Orally Administered Vaccine Product Portfolios and Specifications
Table 81. GSK Orally Administered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 82. GSK Main Business
Table 83. GSK Latest Developments
Table 84. Sanofi Basic Information, Orally Administered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 85. Sanofi Orally Administered Vaccine Product Portfolios and Specifications
Table 86. Sanofi Orally Administered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 87. Sanofi Main Business
Table 88. Sanofi Latest Developments
Table 89. Lanzhou Institute Basic Information, Orally Administered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 90. Lanzhou Institute Orally Administered Vaccine Product Portfolios and Specifications
Table 91. Lanzhou Institute Orally Administered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 92. Lanzhou Institute Main Business
Table 93. Lanzhou Institute Latest Developments
Table 94. Serum Institute Basic Information, Orally Administered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 95. Serum Institute Orally Administered Vaccine Product Portfolios and Specifications
Table 96. Serum Institute Orally Administered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 97. Serum Institute Main Business
Table 98. Serum Institute Latest Developments
Table 99. Valneva Basic Information, Orally Administered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 100. Valneva Orally Administered Vaccine Product Portfolios and Specifications
Table 101. Valneva Orally Administered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 102. Valneva Main Business
Table 103. Valneva Latest Developments
Table 104. Shanghai United Cell Basic Information, Orally Administered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 105. Shanghai United Cell Orally Administered Vaccine Product Portfolios and Specifications
Table 106. Shanghai United Cell Orally Administered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 107. Shanghai United Cell Main Business
Table 108. Shanghai United Cell Latest Developments
Table 109. Bibcol Basic Information, Orally Administered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 110. Bibcol Orally Administered Vaccine Product Portfolios and Specifications
Table 111. Bibcol Orally Administered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 112. Bibcol Main Business
Table 113. Bibcol Latest Developments
Table 114. PaxVax Basic Information, Orally Administered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 115. PaxVax Orally Administered Vaccine Product Portfolios and Specifications
Table 116. PaxVax Orally Administered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 117. PaxVax Main Business
Table 118. PaxVax Latest Developments
Table 119. Vabiotech Basic Information, Orally Administered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 120. Vabiotech Orally Administered Vaccine Product Portfolios and Specifications
Table 121. Vabiotech Orally Administered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 122. Vabiotech Main Business
Table 123. Vabiotech Latest Developments
Table 124. Tiantan Biological Basic Information, Orally Administered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 125. Tiantan Biological Orally Administered Vaccine Product Portfolios and Specifications
Table 126. Tiantan Biological Orally Administered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 127. Tiantan Biological Main Business
Table 128. Tiantan Biological Latest Developments
Table 129. EuBiologics Basic Information, Orally Administered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 130. EuBiologics Orally Administered Vaccine Product Portfolios and Specifications
Table 131. EuBiologics Orally Administered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 132. EuBiologics Main Business
Table 133. EuBiologics Latest Developments
Table 134. Panacea Biotec Ltd Basic Information, Orally Administered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 135. Panacea Biotec Ltd Orally Administered Vaccine Product Portfolios and Specifications
Table 136. Panacea Biotec Ltd Orally Administered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 137. Panacea Biotec Ltd Main Business
Table 138. Panacea Biotec Ltd Latest Developments
Table 139. Bio-Med Basic Information, Orally Administered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 140. Bio-Med Orally Administered Vaccine Product Portfolios and Specifications
Table 141. Bio-Med Orally Administered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 142. Bio-Med Main Business
Table 143. Bio-Med Latest Developments
Table 144. Halfkin Bio-Pharmaceuticals Basic Information, Orally Administered Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 145. Halfkin Bio-Pharmaceuticals Orally Administered Vaccine Product Portfolios and Specifications
Table 146. Halfkin Bio-Pharmaceuticals Orally Administered Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 147. Halfkin Bio-Pharmaceuticals Main Business
Table 148. Halfkin Bio-Pharmaceuticals Latest Developments
LIST OF FIGURES
Figure 1. Picture of Orally Administered Vaccine
Figure 2. Orally Administered Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Orally Administered Vaccine Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Orally Administered Vaccine Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Orally Administered Vaccine Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Orally Administered Vaccine Sales Market Share by Country/Region (2025)
Figure 10. Orally Administered Vaccine Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Rotavirus Vaccine
Figure 12. Product Picture of Cholera Vaccine
Figure 13. Product Picture of Oral Polio Vaccine
Figure 14. Product Picture of Other
Figure 15. Global Orally Administered Vaccine Sales Market Share by Type in 2026
Figure 16. Global Orally Administered Vaccine Revenue Market Share by Type (2021-2026)
Figure 17. Orally Administered Vaccine Consumed in Public
Figure 18. Global Orally Administered Vaccine Market: Public (2021-2026) & (K Units)
Figure 19. Orally Administered Vaccine Consumed in Private
Figure 20. Global Orally Administered Vaccine Market: Private (2021-2026) & (K Units)
Figure 21. Global Orally Administered Vaccine Sale Market Share by Application (2025)
Figure 22. Global Orally Administered Vaccine Revenue Market Share by Application in 2026
Figure 23. Orally Administered Vaccine Sales by Company in 2026 (K Units)
Figure 24. Global Orally Administered Vaccine Sales Market Share by Company in 2026
Figure 25. Orally Administered Vaccine Revenue by Company in 2026 ($ millions)
Figure 26. Global Orally Administered Vaccine Revenue Market Share by Company in 2026
Figure 27. Global Orally Administered Vaccine Sales Market Share by Geographic Region (2021-2026)
Figure 28. Global Orally Administered Vaccine Revenue Market Share by Geographic Region in 2026
Figure 29. Americas Orally Administered Vaccine Sales 2021-2026 (K Units)
Figure 30. Americas Orally Administered Vaccine Revenue 2021-2026 ($ millions)
Figure 31. APAC Orally Administered Vaccine Sales 2021-2026 (K Units)
Figure 32. APAC Orally Administered Vaccine Revenue 2021-2026 ($ millions)
Figure 33. Europe Orally Administered Vaccine Sales 2021-2026 (K Units)
Figure 34. Europe Orally Administered Vaccine Revenue 2021-2026 ($ millions)
Figure 35. Middle East & Africa Orally Administered Vaccine Sales 2021-2026 (K Units)
Figure 36. Middle East & Africa Orally Administered Vaccine Revenue 2021-2026 ($ millions)
Figure 37. Americas Orally Administered Vaccine Sales Market Share by Country in 2026
Figure 38. Americas Orally Administered Vaccine Revenue Market Share by Country (2021-2026)
Figure 39. Americas Orally Administered Vaccine Sales Market Share by Type (2021-2026)
Figure 40. Americas Orally Administered Vaccine Sales Market Share by Application (2021-2026)
Figure 41. United States Orally Administered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 42. Canada Orally Administered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 43. Mexico Orally Administered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 44. Brazil Orally Administered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 45. APAC Orally Administered Vaccine Sales Market Share by Region in 2026
Figure 46. APAC Orally Administered Vaccine Revenue Market Share by Region (2021-2026)
Figure 47. APAC Orally Administered Vaccine Sales Market Share by Type (2021-2026)
Figure 48. APAC Orally Administered Vaccine Sales Market Share by Application (2021-2026)
Figure 49. China Orally Administered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 50. Japan Orally Administered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 51. South Korea Orally Administered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 52. Southeast Asia Orally Administered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 53. India Orally Administered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 54. Australia Orally Administered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 55. China Taiwan Orally Administered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 56. Europe Orally Administered Vaccine Sales Market Share by Country in 2026
Figure 57. Europe Orally Administered Vaccine Revenue Market Share by Country (2021-2026)
Figure 58. Europe Orally Administered Vaccine Sales Market Share by Type (2021-2026)
Figure 59. Europe Orally Administered Vaccine Sales Market Share by Application (2021-2026)
Figure 60. Germany Orally Administered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 61. France Orally Administered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 62. UK Orally Administered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 63. Italy Orally Administered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 64. Russia Orally Administered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 65. Middle East & Africa Orally Administered Vaccine Sales Market Share by Country (2021-2026)
Figure 66. Middle East & Africa Orally Administered Vaccine Sales Market Share by Type (2021-2026)
Figure 67. Middle East & Africa Orally Administered Vaccine Sales Market Share by Application (2021-2026)
Figure 68. Egypt Orally Administered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 69. South Africa Orally Administered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 70. Israel Orally Administered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 71. Turkey Orally Administered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 72. GCC Countries Orally Administered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 73. Manufacturing Cost Structure Analysis of Orally Administered Vaccine in 2026
Figure 74. Manufacturing Process Analysis of Orally Administered Vaccine
Figure 75. Industry Chain Structure of Orally Administered Vaccine
Figure 76. Channels of Distribution
Figure 77. Global Orally Administered Vaccine Sales Market Forecast by Region (2027-2032)
Figure 78. Global Orally Administered Vaccine Revenue Market Share Forecast by Region (2027-2032)
Figure 79. Global Orally Administered Vaccine Sales Market Share Forecast by Type (2027-2032)
Figure 80. Global Orally Administered Vaccine Revenue Market Share Forecast by Type (2027-2032)
Figure 81. Global Orally Administered Vaccine Sales Market Share Forecast by Application (2027-2032)
Figure 82. Global Orally Administered Vaccine Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of Orally Administered Vaccine
Figure 2. Orally Administered Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Orally Administered Vaccine Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global Orally Administered Vaccine Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. Orally Administered Vaccine Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. Orally Administered Vaccine Sales Market Share by Country/Region (2025)
Figure 10. Orally Administered Vaccine Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Rotavirus Vaccine
Figure 12. Product Picture of Cholera Vaccine
Figure 13. Product Picture of Oral Polio Vaccine
Figure 14. Product Picture of Other
Figure 15. Global Orally Administered Vaccine Sales Market Share by Type in 2026
Figure 16. Global Orally Administered Vaccine Revenue Market Share by Type (2021-2026)
Figure 17. Orally Administered Vaccine Consumed in Public
Figure 18. Global Orally Administered Vaccine Market: Public (2021-2026) & (K Units)
Figure 19. Orally Administered Vaccine Consumed in Private
Figure 20. Global Orally Administered Vaccine Market: Private (2021-2026) & (K Units)
Figure 21. Global Orally Administered Vaccine Sale Market Share by Application (2025)
Figure 22. Global Orally Administered Vaccine Revenue Market Share by Application in 2026
Figure 23. Orally Administered Vaccine Sales by Company in 2026 (K Units)
Figure 24. Global Orally Administered Vaccine Sales Market Share by Company in 2026
Figure 25. Orally Administered Vaccine Revenue by Company in 2026 ($ millions)
Figure 26. Global Orally Administered Vaccine Revenue Market Share by Company in 2026
Figure 27. Global Orally Administered Vaccine Sales Market Share by Geographic Region (2021-2026)
Figure 28. Global Orally Administered Vaccine Revenue Market Share by Geographic Region in 2026
Figure 29. Americas Orally Administered Vaccine Sales 2021-2026 (K Units)
Figure 30. Americas Orally Administered Vaccine Revenue 2021-2026 ($ millions)
Figure 31. APAC Orally Administered Vaccine Sales 2021-2026 (K Units)
Figure 32. APAC Orally Administered Vaccine Revenue 2021-2026 ($ millions)
Figure 33. Europe Orally Administered Vaccine Sales 2021-2026 (K Units)
Figure 34. Europe Orally Administered Vaccine Revenue 2021-2026 ($ millions)
Figure 35. Middle East & Africa Orally Administered Vaccine Sales 2021-2026 (K Units)
Figure 36. Middle East & Africa Orally Administered Vaccine Revenue 2021-2026 ($ millions)
Figure 37. Americas Orally Administered Vaccine Sales Market Share by Country in 2026
Figure 38. Americas Orally Administered Vaccine Revenue Market Share by Country (2021-2026)
Figure 39. Americas Orally Administered Vaccine Sales Market Share by Type (2021-2026)
Figure 40. Americas Orally Administered Vaccine Sales Market Share by Application (2021-2026)
Figure 41. United States Orally Administered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 42. Canada Orally Administered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 43. Mexico Orally Administered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 44. Brazil Orally Administered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 45. APAC Orally Administered Vaccine Sales Market Share by Region in 2026
Figure 46. APAC Orally Administered Vaccine Revenue Market Share by Region (2021-2026)
Figure 47. APAC Orally Administered Vaccine Sales Market Share by Type (2021-2026)
Figure 48. APAC Orally Administered Vaccine Sales Market Share by Application (2021-2026)
Figure 49. China Orally Administered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 50. Japan Orally Administered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 51. South Korea Orally Administered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 52. Southeast Asia Orally Administered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 53. India Orally Administered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 54. Australia Orally Administered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 55. China Taiwan Orally Administered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 56. Europe Orally Administered Vaccine Sales Market Share by Country in 2026
Figure 57. Europe Orally Administered Vaccine Revenue Market Share by Country (2021-2026)
Figure 58. Europe Orally Administered Vaccine Sales Market Share by Type (2021-2026)
Figure 59. Europe Orally Administered Vaccine Sales Market Share by Application (2021-2026)
Figure 60. Germany Orally Administered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 61. France Orally Administered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 62. UK Orally Administered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 63. Italy Orally Administered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 64. Russia Orally Administered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 65. Middle East & Africa Orally Administered Vaccine Sales Market Share by Country (2021-2026)
Figure 66. Middle East & Africa Orally Administered Vaccine Sales Market Share by Type (2021-2026)
Figure 67. Middle East & Africa Orally Administered Vaccine Sales Market Share by Application (2021-2026)
Figure 68. Egypt Orally Administered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 69. South Africa Orally Administered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 70. Israel Orally Administered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 71. Turkey Orally Administered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 72. GCC Countries Orally Administered Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 73. Manufacturing Cost Structure Analysis of Orally Administered Vaccine in 2026
Figure 74. Manufacturing Process Analysis of Orally Administered Vaccine
Figure 75. Industry Chain Structure of Orally Administered Vaccine
Figure 76. Channels of Distribution
Figure 77. Global Orally Administered Vaccine Sales Market Forecast by Region (2027-2032)
Figure 78. Global Orally Administered Vaccine Revenue Market Share Forecast by Region (2027-2032)
Figure 79. Global Orally Administered Vaccine Sales Market Share Forecast by Type (2027-2032)
Figure 80. Global Orally Administered Vaccine Revenue Market Share Forecast by Type (2027-2032)
Figure 81. Global Orally Administered Vaccine Sales Market Share Forecast by Application (2027-2032)
Figure 82. Global Orally Administered Vaccine Revenue Market Share Forecast by Application (2027-2032)
